Anixa Biosciences Inc

Health Care
Biotechnology: Pharmaceutical Preparations
www.anixa.com

Market Cap $96.37K
PE -0
Debt $NaN
Cash $1.23M
EV $NaN
FCF $NaN

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$12.51M
EBIT	-$13.72M
ROE	-57%
ROA	-60%
Equity	$21.77M
Growth Stability	1
PE	-0.01
PB	0
Price/Cash	12.71
Sales CAGR	0%
Equity CAGR	31%
Earnings Growth YoY	30%
Earnings Growth QoQ	4%

Sales CAGR 5Y	-0%
Equity CAGR 5Y	36%
Equity CAGR 3Y	-16%
Market Cap	$96.37K
Assets	$22.91M
Cash	$1.23M
Shares Outstanding	31.8K
Working Capital	20.67M
Current Ratio	11.31
Shares Growth 3y	3%
Equity Growth QoQ	-8%
Equity Growth YoY	-15%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Anixa Biosciences Inc, a cancer-focused biotechnology company, is engaged in harnessing the body's immune system in the fight against cancer. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. It is developing the CchekTM platform, a series of inexpensive non-invasive blood tests for early detection of solid tumours which is based on the body's immune response to the presence of a malignancy. The company is also developing chimeric antigen receptor T-cell (CAR-T) based immuno-therapy drugs that genetically engineer patient's own immune cells to fight cancer.

SEC Filings

Direct access to Anixa Biosciences Inc (ANIX) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Jul 31
- 10-Q Apr 30
- 10-Q Jan 31
2023
- 10-K Oct 31
- 10-Q Jul 31
- 10-Q Apr 30
- 10-Q Jan 31
2022
- 10-K Oct 31
- 10-Q Jul 31
- 10-Q Apr 30
- 10-Q Jan 31

Sector Comparison

How does Anixa Biosciences Inc compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Anixa Biosciences Inc compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Anixa Biosciences Inc Discounted Cash Flow

Fully customizable DCF calculator online for Anixa Biosciences Inc.

Years

Calculation mode

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
DCF		$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Value	$0

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	10/2015	10/2016	10/2017	10/2018	10/2019	10/2020	10/2021	10/2022	10/2023	TTM
Net Margins	-15%	-2K%	-2K%	-1K%	-5K%	-	-3K%	-	-5K%	-
ROA	-	-80%	-51%	-222%	-189%	-106%	-36%	-46%	-43%	-60%
ROE	-	-508%	-89%	-262%	-226%	-115%	-37%	-47%	-41%	-57%

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	10/2015	10/2016	10/2017	10/2018	10/2019	10/2020	10/2021	10/2022	10/2023	TTM
Debt over FCF	-	-0.13	-	-	-	-	-	-	-	-
Debt over Equity	0.15	0.47	-	-	-	-	-	-	-	-
Growth Stability	-	-	-	-	-	-	-	-	-	1

Neutral Debt/FCF ratio (-)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Neutral Debt/Equity ratio (-)

The company has a balance between equity and debt that is not too good nor too bad.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	10/2015	10/2016	10/2017	10/2018	10/2019	10/2020	10/2021	10/2022	10/2023	CAGR 5Y
Revenue YoY growth	-	-97%	21%	207%	-78%	-	-	-	-	-0%
Earnings YoY growth	-	264%	40%	103%	-17%	-15%	30%	5%	-28%	-
Equity YoY growth	-	-80%	702%	-31%	-4%	67%	304%	-18%	-16%	36%
FCF YoY growth	-	-370%	8%	13%	14%	26%	-	-	-	-